Reshaping the HIV treatment and prevention landscape
HIV delivering mid-single digit % sales CAGR 2021-26
with pipeline optionality beyond
Illustrative
Mature products
Growth drivers
2021
+ Dovato
+ Cabenuva
+ Cab PrEP
-
-
Triumeq
Tivicay
Growth drivers
Mature products
HIV mid
single
digit %
CAGR
Post 2026 LA
pipeline potential
for revenue
renewal
2026
Note: Bars are not at scale. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and
assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards.
gsk
73View entire presentation